Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its ...

Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up ...

The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully ...

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...